Global Microbiome Competitive Landscape Report 2023: Comprehensive Insights on 130+ Companies and 180+ Drugs
April 28, 2023 09:53 ET
|
Research and Markets
Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Microbiome - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "Microbiome- Competitive landscape, 2023"...
Finch Therapeutics Announces Executive Leadership Transitions
April 25, 2023 16:05 ET
|
Finch Therapeutics Group, Inc.
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
April 25, 2023 10:00 ET
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
April 18, 2023 16:01 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Verb Biotics announces participation in Ginkgo Bioworks’ annual Ferment conference
April 18, 2023 11:25 ET
|
Verb Biotics
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Verb Biotics, a microbiome innovation company, today announced that it will be participating as a next-generation biotech innovator at Ferment, Ginkgo...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
April 04, 2023 08:00 ET
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...
Global Gut Microbiome Growth Opportunities 2023: Targeted Gut Microbiome Technologies to Drive Transformational Growth Across the Global Healthcare Landscape
April 03, 2023 05:33 ET
|
Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Gut Microbiome Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study identifies and analyzes research...
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
March 30, 2023 03:00 ET
|
Trobix Bio
Netanya, Israel, March 30, 2023 - Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced precision microbiome oncology therapeutics, announced today the...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
March 29, 2023 08:00 ET
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
March 28, 2023 03:00 ET
|
EnteroBiotix
GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...